Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Ventricular Tachycardia Ablation Through Radiation Therapy Consortium: Concept Description of an Observational Retrospective Multicentric Trial

A legfontosabb adatok

Ki végzi
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hol
Olaszország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
149 fő vett részt
Kezdés
2025. márc. 30.
Várható befejezés
2029. márc. 30.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2025. május 25.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Diagnosis of refractory ventricular tachycardia (VT), as previously defined
  • Age greater than 18 years
  • Presence of an implantable cardioverter-defibrillator (ICD) for follow-up
  • Not eligible for heart transplantation
  • Estimated life expectancy of at least 1 year
  • Ability to provide autonomous, informed consent to participate in the study

Ki nem vehet részt

  • Patients with active neoplastic disease under oncological treatment
  • ICD interrogation demonstrating polymorphic VT
  • Patients with INTERMACS class more than 4
  • Patients with LVADs

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Recurrent ventricular tachycardia (VT) is a potentially life-threatening arrhythmia in patients with structural heart disease. Despite the use of antiarrhythmic drugs, implantable cardioverter-defibrillators (ICDs), and radiofrequency catheter ablation, VT recurrence rates remain high-reaching up to 66% in some series. For patients with refractory VT who are not candidates for further ablation or surgical interventions, there is a significant unmet need for novel, effective, and non-invasive treatment options.

A teljes eredeti leírásKevesebb

Stereotactic body radiation therapy (SBRT) has recently emerged as a promising approach for treating ventricular arrhythmias through a technique known as stereotactic arrhythmia radioablation (STAR). Preliminary studies, including a phase I/II clinical trial, have demonstrated a substantial reduction in VT burden-up to 99.9%-following treatment, with an acceptable safety profile. Reported adverse events have included manageable pericardial effusion, radiation-induced pericarditis, and pneumonitis. The growing body of evidence supports STAR as a feasible and effective alternative for selected patients with treatment-resistant VT.

The objective of this study is to evaluate the efficacy and safety of stereotactic radiotherapy as a non-invasive ablation technique for the treatment of ventricular tachycardia (VT) in patients with refractory arrhythmias in whom conventional therapies have failed.

This is a retrospective observational study aimed at comparing outcomes between patients who received stereotactic radioablation and those who did not. A matched-pair analysis will be used to adjust for baseline clinical characteristics and ensure comparability between groups.

A vizsgálat 2 csoportja

  • patients who have undergone SBRT

    Within this group we find patients who have had all possible canonical treatments for the arrhythmia and also the stereotactic radiation treatment

  • patients who have not undergone SBRT

    Within this group we find patients who have had all possible canonical treatments for the arrhythmia, but not the stereotactic radiation treatment

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Ventricular Tachycardia Ablation Through Radiation Therapy Consortium: Concept Description of an Observational Retrospective Multicentric Trial Via Matched Pair Analysis (VT-ARTr)
A regiszteradat frissítve
2025. május 25.